EMERCell Receives Strategic Investment from Onward Therapeutics

22 Feb, 2021

EMERCell Receives Strategic Investment from Onward Therapeutics
Photo by Wesson Wang on Unsplash

Onward Therapeutics from Montpellier, France, invested in EMERCell.
– The amount of the deal was not disclosed.
– EMERCell SAS is a company that has developed a platform technology to produce off-the-shelf natural killer (NK) cells.
Onward Therapeutics became the majority shareholder after it invested in EMERCell SAS.

Biopharma Biotechnology Europe Therapeutics
Crunchbase icon

Content report

The following text will be sent to our editors: